Rezolute (RZLT) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
11 Jan, 2026Opening remarks and agenda
The meeting was called to order and webcast live, with instructions for virtual participation and Q&A provided.
The agenda included election of directors, auditor ratification, executive compensation, share increase, stock incentive plan amendment, and potential adjournment.
Board and executive committee updates
Six directors were nominated for election as detailed in the proxy statement.
Shareholder proposals
Proposals included electing directors, ratifying the auditor, approving executive compensation, increasing authorized shares, amending the stock incentive plan, and potential adjournment.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Rezolute
- Late-stage antibody therapy targets refractory hypoglycemia in HI, with $1B+ market potential.RZLT
Corporate presentation29 Jun 2026 - Pivotal data and regulatory milestones support dual BLA filings and strong market prospects in 2025.RZLT
Jefferies Global Healthcare Conference 202614 Jun 2026 - Phase 3 data showed strong efficacy for ersodetug in HI; net loss narrowed as R&D costs fell.RZLT
Q3 202612 May 2026 - Ersodetug advances in Phase 3 for HI, targeting a $1B+ rare disease market with FDA engagement.RZLT
Corporate presentation8 May 2026 - Late-stage antibody therapy targets severe hypoglycemia in rare hyperinsulinism, with $1B+ potential.RZLT
Corporate presentation1 Apr 2026 - Net loss widened to $22.8M; cash and investments at $132.9M, with key trials ongoing.RZLT
Q2 202612 Feb 2026 - Antibody therapy for hyperinsulinism shows strong efficacy and targets rare disease markets.RZLT
Guggenheim Securities Inaugural Healthcare Innovation Conference14 Jan 2026 - Ersodetug offers a novel solution for severe hypoglycemia in rare HI, targeting a $1B+ market.RZLT
Corporate Presentation9 Jan 2026 - Phase III data for a universal hyperinsulinism therapy expected in December, with BLA filing mid-2026.RZLT
Morgan Stanley 23rd Annual Global Healthcare Conference31 Dec 2025